in Re Purdue Pharma L.P.

Opinion

Opinion issued August 23, 2019

In The

Court of Appeals For The

First District of Texas ———————————— NO. 01-19-00551-CV ——————————— IN RE PURDUE PHARMA L.P., ET AL., Relators

Original Proceeding on Petition for Writ of Mandamus

MEMORANDUM OPINION

Relators, Purdue Pharma L.P., Purdue Pharma Inc., The Purdue Frederick

Company, Johnson & Johnson, Janssen Pharmaceutica Inc. n/k/a Janssen

Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen

Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc., Endo Health Solutions

Inc., Endo Pharmaceuticals Inc., Allergan plc f/k/a Actavis plc, Allergan Finance,

LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc., Watson Laboratories,

Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., Knoll Pharmaceutical Co. and AbbVie Inc. (collectively “Manufacturer Defendants”),

have filed a petition for a writ of mandamus challenging the trial court’s orders

denying the Manufacturer Defendants’ first amended joint motions to dismiss the

claims of real parties in interest, the Counties of Dallas, Delta, Falls, Hopkins, and

Travis, under Texas Rule of Civil Procedure 91a.1

We deny the petition.

PER CURIAM

Panel consists of Justices Lloyd, Goodman, and Landau.

1 The underlying case is In re: Texas Opioid Litigation, Cause No. 2018-63587, in the 152nd District Court of Harris County, Texas, the Honorable Robert K. Schaffer presiding.